Intuitive Surgical reporting changes likely immaterial, says Lazard Capital Lazard Capital believes the changes Intuitive Surgical made to its adverse events reporting are likely to prove immaterial and keeps a Buy rating on the stock with a $625 price target. However, the firm thinks the changes could put pressure on the stock.
News For ISRG From The Last 14 Days
Check below for free stories on ISRG the last two weeks.
Intuitive Surgical Monopolar shipments have resumed, says SunTrust SunTrust's checks confirm that Intuitive Surgical has resumed shipments of a new updated version of its Monopolar Scissors and believes the impact from the urgent notification and the stop shipment that has been in place for three weeks has been minimal. Shares are Buy rated with a $647 rice target.